Furthermore, because the TMB and/or the PD-L1 expression did not precisely identify patients who were more likely to derive benefit from immunotherapy [34,35], the assessment of tumour-related or immune-related gene signatures was actively investigated. Here, CD274 is linked to neoplasm.